InfuSystem Holdings, Inc — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
InfuSystem reported Q2 2026 net revenues of $36.9M (up 2.6% YoY, or 7.5% pro-forma after adjusting for $1.6M GE Healthcare contract restructuring). Net income was $3.2M ($0.15 per diluted share); Adjusted EBITDA $8.6M (23.4% margin, up 110 bps). Patient Services drove 15% growth to $24.8M; Device Solutions declined 16% to $12.1M due to GE contract reduction. Company reaffirmed full-year 2026 guidance of 6–8% pro-forma revenue growth and mid-to-low 20% Adjusted EBITDA margin. Share repurchases totaled $3.5M in the quarter; liquidity stands at $55.2M.
Why this rating
Solid Q2 execution with modest nominal growth, margin expansion, and reaffirmed guidance. Pro-forma 7.5% growth is healthy. Counterparties (GE, unnamed compression device suppliers) are not material individually. Event is routine earnings disclosure—no major operational, capital, or strategic change.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.